Immix Biopharma Investor Presentation Deck
Upcoming Catalysts
I NXC-201
✓2023 - Ongoing Phase 1b/2 results with NXC-201
Data pending release: relapsed/refractory
Multiple Myeloma - 63 patients treated
✓ Data pending release: relapsed/refractory
AL amyloidosis - 9 patients treated
✔ Data pending release: More patients (current
enrollment pace -5 patients/month)
✓2023 - Pre-IND meeting with FDA
✓2023 - File IND for U.S. Phase 1b/2 trial for NXC-201
I✓ 2023 Q4 - US clinical trial open
✓2H25 - Planned Biologics License Applications (BLA)
submission for NXC-201 once 100 patients are dosed
IMMIX
BIOPHARMA
●●●
IMMIX
S BIOPHARMA
IMX-110
✓ 2023 - Release data on a rolling basis from Phase
1b/2a advanced solid tumor trial with IMX-110 +
tislelizumab combination therapy
✓ 2023 - Continue enrolling patients into Phase 1b/2a
trial evaluating IMX-110 in STS
✓ 2023 - Ongoing preclinical studies with IMX-110
✓2023 - Add Phase 2a clinical sites for IMX-110
✓ 2024 - Report Phase interim 2a results for IMX-110 I
in STS
Other Candidates
✓ 2H23 - Finish preclinical studies with IMX-111
✓ 2H23 - Finish preclinical studies with IMX-120
26View entire presentation